Skip to content

KEY-VALUE: Survey on the Treatment Pattern of 1L Immunotherapy in Chinese Advanced NSCLC Patients

KEY-VALUE: Survey on the Treatment Pattern of 1L Immunotherapy in Chinese Advanced NSCLC Patients

Status
Recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400079700
Enrollment
Unknown
Registered
2024-01-10
Start date
2024-06-13
Completion date
Unknown
Last updated
2025-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ADVANCED NSCLC

Interventions

Qualitative interview:NA
Quantitative interview:NA

Sponsors

Shanghai Geriatric Medical Center
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1) Must be experienced in managing NSCLC patients specializing in oncology, radiation oncology or thoracic surgery (qualified attending/vice chief/chief physician who has at least 2 years of experiences in managing patients with advanced NSCLC) 2) Experienced of immunotherapy of 1L mNSCLC patients: • For participants from Tier 1-2 city, treatment of at least 5 patients with 1L anti-PD-1/L1 inhibitors in past 3 months is required • For participants from Tier 3-5 city, 1L IO treatment of mNSCLC patients in past 6 months is required 3) At least 60% of the time spent in direct patient care

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

MeasureTime frame
Treatment patterns and most common 1L utilization of IO in advanced NSCLC patients in China;

Secondary

MeasureTime frame
To identify key factors of decision making of real-world clinical practice of 1L IO treatment in NSCLC patients, from Chinese doctors with different department;

Countries

China

Contacts

Public ContactJie Hu

Shanghai Geriatric Medical Center

hu.jie@zs-hospital.sh.cn+86 21 5137 1990

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026